New Biannual Vaccine Shows Promise in Controlling High Blood Pressure

Researchers at Queen Mary University of London have tested a novel treatment called ‘Zilbeciran’ that can control high blood pressure with just two injections per year. The ‘CARDIA-2’ study involved 663 adult participants, and the drug demonstrated significant reductions in blood pressure alongside standard medications. Zilbeciran works by inhibiting the production of the protein angiotensinogen in the body, delivering long-lasting effects via a single injection every six months. The second phase of clinical trials is currently underway. Kathmandu, March 14.

This development offers hope to patients with hypertension by potentially freeing them from the burden of daily medication. Led by researchers from Queen Mary University of London, the global trial revealed that administering the vaccine twice yearly could effectively maintain blood pressure control. The experimental drug showed positive outcomes particularly for patients whose hypertension was not adequately managed by conventional treatments.

By targeting a specific protein produced in the liver, Zilbeciran promotes vasodilation, thereby lowering blood pressure. When given alongside standard therapy, the injection resulted in a significant decrease in blood pressure levels. One of its most notable advantages is its prolonged effect, requiring only one dose every six months, reducing the risk of patients forgetting daily pills.

The ongoing second phase trial aims to further investigate how much this treatment can reduce the risks of heart attack and stroke, with additional studies set to begin within this year. Dr. Manish Saxena, senior author of the study and hypertension specialist, described this new approach as a ‘game-changer.’ He stated, “High blood pressure is a global health challenge, and only a small percentage of people achieve effective control. This new therapy could help millions worldwide manage their condition more effectively.”